Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

Hope S. Rugo, MD, FASCO, emphasized the importance of educating patients about proactive rash and diarrhea management while taking PI3K/AKT inhibitors.

Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for patients with cancer.

Understanding How On-Target and Off-Target ADC Toxicities Work

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Michelle Kirschner, RN, MSN, ACNP, APRN-BC, is a nurse practitioner and director of program development at the Cancer Survivorship and Supportive Care Professionals Network.

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

Survivorship expert Michelle Kirschner, MSN, RN, ACNP, APRN-BC, says that “doable changes” can enhance the lives of patients surviving cancer.

Diet, Exercise Help Patients “Flourish” In Cancer Survivorship

Articles

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

July FDA Oncology Approvals Include Options for NSCLC, Myeloma, and More

Adding aprepitant to chemotherapy was linked to longer survival in patients with non-luminal breast cancers, especially triple-negative breast cancer.

Adding Aprepitant to Chemo Extends Non-Luminal Breast Cancer Survival 

Ronald Bleday, MD, is the section chief of the Division of Colorectal Surgery and vice chair for quality and patient safety in the Department of Surgery at Brigham and Women’s Hospital in Boston, Massachusetts.

Experienced oncology nurses and APPs can help nurses newer to the field understand who is more at risk of opioid addiction, says expert Ronald Bleday, MD.

Nurse-Peer Mentorship Can Help Prevent Opioid Addiction in Post-Op CRC

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Study Hall powered by, Oncology Nursing News is a dedicated hub designed for Advanced Practice Providers, offering an easy-to-navigate platform to support your clinical practice. Explore a comprehensive collection of articles, videos and learning modules.

Study Hall

The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.

FDA Declines Breakthrough Status, Halts Itolizumab’s Path Forward in Acute GVHD

Pacritinib showed early activity and was safe for patients with multi-refractory chronic graft-vs-host disease.

Pacritinib Shows Preliminary ORR in Chronic Graft-Vs-Host Disease

MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.

MaaT013 Achieves Primary Endpoint in ARES Trial for GI-aGVHD

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy. 

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Treatment with Axatilimab in Chronic GVHD: How it Works and Insights into Treatment Efficacy 

Video content above is prompted by the following:

Can you tell us about axatilimab and its potential role in cGVHD treatment? How does its mechanism of action differ from other therapies? Please briefly highlight the AGAVE-201 trial and data.

Panelists conclude by discussing the future of graft-versus-host disease management, expressing their hopes for the current treatment landscape and potential advancements that could further improve patient outcomes and quality of life.

Looking Ahead: The Future of Chronic GVHD Management and Patient Care 

Panelists discuss how axatilimab, a novel therapy for chronic graft-versus-host disease (cGVHD), functions through a unique mechanism of action compared to other treatments, highlighting its potential role in cGVHD management and presenting key findings from the AGAVE-201 trial that demonstrate its efficacy and safety profile.

Chronic GVHD Treatment Overview: Immunosuppressives, New Agents, and What Patients Need to Know 

Let's discuss the current treatment landscape for cGVHD, including emerging therapies and their potential impact on patient care.

Can you provide an overview of the current treatment approaches for cGVHD? Please highlight GVHD management relies on immunosuppressive treatments like corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Several agents have been approved for various GVHD settings, including axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept.

What key things should patients be aware of when receiving therapies?

Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin inhibitors to newer approved agents like axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept, emphasizing key considerations patients should be aware of when undergoing these therapies.

Patient Communication and Collaborative Care for Symptom Management

As a PA, what strategies do you use to help patients recognize and report their symptoms effectively?

How do you counsel patients and caregivers on identifying, managing, and communicating (to who: e.g. nurse navigator, pharmacists, patient portal) these symptoms with their healthcare team?

Please provide an example or 2 of what that patient conversation looks like.

Can you walk us through your process for developing and adjusting symptom management plans for cGVHD patients? How do you involve patients in this process?

What are some of the most challenging symptoms to manage in cGVHD patients, and how do you approach these challenges?

How do you collaborate with other members of the healthcare team to ensure comprehensive symptom management for cGVHD patients?

Panelists discuss how physician assistants educate and empower chronic graft-versus-host disease patients and their caregivers to recognize, report, and manage symptoms effectively, detailing strategies for patient communication, developing personalized symptom management plans, addressing challenging symptoms, and collaborating with the broader healthcare team to ensure comprehensive care.

Early Symptom Detection and the Impact on Patient Outcomes in GVHD

Now, let's focus on the crucial role that the care team plays in identifying and managing symptoms for cGVHD patients, particularly those with advanced disease.

What are the key symptoms you look for when assessing cGVHD patients? How do you approach symptom identification, especially for those with advanced disease?

Can you explain the importance of early symptom identification and management in cGVHD? How does this affect patient outcomes?

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, approaches to symptom identification, and the critical importance of early detection and management for improving patient outcomes.

Managing Severe Symptoms and Disease Progression in the GVHD Journey

Can you describe the typical disease course for cGVHD patients, particularly those who progress to third-line treatment and beyond? What are some of the most severe symptoms they face?

How does the burden of cGVHD impact a patient's quality of life, and what are some of the long-term consequences if symptoms are not properly managed?

Panelists discuss how chronic graft-versus-host disease typically progresses in patients requiring third-line treatment and beyond, focusing on severe symptoms, the impact on quality of life, and potential long-term consequences of inadequately managed symptoms.

Comprehensive Patient Education and Symptom Awareness with GVHD

As an NP, how do you approach educating patients about cGVHD and its potential long-term effects? What resources or educational materials have you found most helpful in supporting patients and their caregivers? (brochures, apps, websites, videos?)

Panelists discuss how nurse practitioners educate patients about chronic graft-versus-host disease (cGVHD) and its long-term effects, exploring various educational resources and materials such as brochures, apps, websites, and videos that are most effective in supporting patients and their caregivers.

Chronic Graft-versus-Host Disease: Understanding the Disease and Its Widespread Symptoms

Can you provide some background on cGVHD? How does it differ from acute GVHD, and what are the main challenges it presents for patients?

From your experience, what are the most common symptoms you see in cGVHD patients, and how do these symptoms impact their daily lives?

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

Graft-Vs-Host Disease

Latest News

Study Hall

Latest Conference Coverage